Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Vaccines
Scientists at Engelhardt Institute of Molecular Biology report research in HIV/AIDS vaccines
November 12th, 2008
New research, 'HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response,' is the subject of a report. "Targeting of a DNA vaccine encoded protein for degradation via the proteasome is attempted since it may enhance the immunogenicity of the vaccine. We have fused HIV-1 reverse transcriptase (RT) to mouse ornithine decarboxylase (ODC), a protein rapidly degraded by proteasome in an ubiquitine-independent fashion, to enhance the introduction of RT into the MHC class I pathway," investigators in Russia report. "We also designed a fusion of RT with two short signals from the C-terminus of ODC (ODCsig)...
Source: Vaccine Weekly (2008-11-12)
|
